Fasting Clinical Trial
Official title:
A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg of With Zebeta® 10 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult human subjects.
Status | Completed |
Enrollment | 24 |
Est. completion date | November 2012 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Male and Non-pregnant female human subjects, age in the range of 18 - 45 years (both inclusive). 2. Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart. 3. Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and oral temperature). 4. Subjects with clinically acceptable findings as determined by haemogram, biochemistry, serology (HIV, Hepatitis B and Hepatitis C), urinalysis, 12 lead ECG and chest X-ray (chest X-ray if required). 5. Willingness to follow the protocol requirements as evidenced by written informed consent. 6. Subject willing to give written informed consent. 7. Confirming and agreeing to, not using any prescription and over the counter medications including vitamins and minerals for 14 days prior to study and during the course of the study. 8. No history of drug abuse in the past one year. 9. Non-smokers and non-alcoholics. 10. For female subject - was child bearing potential practicing acceptable method of birth control for the duration of the study as judged by Investigator such as Condom, Foams, Jellies, Diaphragm, Intrauterine device and Abstinence. OR - was surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject). Exclusion Criteria: 1. Known history of hypersensitivity to Bisoprolol Fumarate, or related drugs. 2. Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day. 3. Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc. 4. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases and bleeding tendency. 5. Participation in a clinical drug study or bioequivalence study within 90 days prior to present study. 6. History of malignancy or other serious diseases. 7. Refusal to abstain from food for at least 10.00 hours prior to study drug administration and for at least 04.00 hours post-dose, in each study period. 8. Any contraindication to blood sampling or difficulty in accessibility of veins. 9. Refusal to abstain from fluid for at least 01.00 hour prior to study drug administration and for at least 01.00 additional hour post-dose, in each study period except about 240 mL of water given during administration of study drug. 10. Refusal to avoid the use of xanthine-containing food or beverages (chocolates, tea, coffee or cola drinks) or fruit juice/grapefruit juice and any alcoholic products for 48.00 hours prior to dosing until the last blood sample collection of last study period. 11. Blood donation within 90 days prior to the commencement of the study. 12. Subjects with positive HIV tests or Hepatitis-B or Hepatitis-C tests. 13. Found positive in breath alcohol test done before check-in for each study period. 14. Found positive in urine test for drugs of abuse done before check-in for each study period. 15. Refusal to abstain from consumption of tobacco products 24.00 hours prior to dosing until the last blood sample collection of last study period. 16. History of problem in swallowing Tablet(s). 17. Female subject, demonstrating positive urine pregnancy test at the time of screening. 18. Female subject, demonstrating positive Serum (ß) Beta- hCG (Human Chorionic Gonadotropin) test before check-in for each study period. 19. Female subject, currently breast feeding or lactating. 20. Female subjects not willing to use acceptable method of contraception from the date of screening until the completion of the study. |
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
India | Accutest Research Lab (I) Pvt. Ltd. | Ahmedabad | Gujarat |
Lead Sponsor | Collaborator |
---|---|
IPCA Laboratories Ltd. |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax | pre-dose, 00.50, 01.00, 01.50, 02.00, 02.33, 02.67, 03.00, 03.33, 03.67, 04.00, 04.50, 05.00, 06.00, 07.00, 08.00, 10.00, 12.00, 16.00, 20.00, 24.00, 48.00 and 72.00 hours post-dose | 3 months | No |
Primary | AUC | Pre-dose and at 00.50, 01.00, 01.50, 02.00, 02.33, 02.67, 03.00, 03.33, 03.67, 04.00, 04.50, 05.00, 06.00, 07.00, 08.00, 10.00, 12.00, 16.00, 20.00, 24.00, 48.00 and 72.00 hours post-dose. | 3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03754920 -
Prolonged Fasting With Meditation and Mild Physical Exercise
|
N/A | |
Completed |
NCT05272332 -
Gastric Ultrasound Prior to Extubation
|
||
Completed |
NCT04247464 -
Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients
|
N/A | |
Completed |
NCT01067001 -
Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study
|
N/A | |
Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
Completed |
NCT01506713 -
Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT04514380 -
Effect of Drinking Carbohydrate-containing Fluids on Gastric Residual Volume in Elderly Patients
|
||
Completed |
NCT05756868 -
The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior
|
N/A | |
Completed |
NCT05134207 -
The Effect of Oral Carbohydrate Solution on Anxiety and Comfort in Patients Undergoing Hip Arthroplasty
|
N/A | |
Completed |
NCT05031598 -
Long-term Fasting: Multi-system Adaptations in Humans
|
N/A | |
Recruiting |
NCT04501393 -
Recommended Clear Fluid Intake Volume at 2 Hours Prior to Esophagogastroduodenoscopy for Adult Patients
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
Completed |
NCT05219136 -
Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol
|
N/A | |
Recruiting |
NCT04625608 -
Effect of Premedicant Oral Paracetamol on Gastric Volume and pH
|
Phase 4 | |
Not yet recruiting |
NCT02562638 -
Pre-Procedural Fasting in Cardiac Intervention
|
N/A | |
Completed |
NCT01949987 -
Does Oral Intake Decreases Postoperative Pain Score in Children
|
N/A | |
Completed |
NCT01954836 -
Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial
|
N/A | |
Completed |
NCT01746719 -
Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition
|
Phase 1 | |
Completed |
NCT01721187 -
Satiety Effects on the Neural Valuation of Food
|
N/A | |
Completed |
NCT01831700 -
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions
|
Phase 1 |